Soluble amyloid β-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration
- 18 March 2011
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences of the United States of America
- Vol. 108 (14), 5819-5824
- https://doi.org/10.1073/pnas.1017033108
Abstract
Alzheimer disease is a major cause of cognitive failure, and a pathogenically related but more subtle process accounts for many cases of mild memory symptoms in older humans. Insoluble fibrillar plaques of amyloid β-proteins (Aβ) and neurofibrillary deposits of hyperphosphorylated tau proteins are the diagnostic lesions of AD, but their temporal mechanistic relationship has long been debated. The recent recognition that small, diffusible oligomers may be the principal bioactive form of Aβ raises the key question of whether these are sufficient to initiate cytoskeletal change and neurite degeneration. A few studies have examined the effects of oligomers of synthetic Aβ peptides of one defined length at supraphysiological concentrations, but the existence of such assemblies in the AD brain is not established. Here, we isolated Aβ dimers, the most abundant form of soluble oligomer detectable in the human brain, from the cortices of typical AD subjects and found that at subnanomolar concentrations, they first induced hyperphosphorylation of tau at AD-relevant epitopes in hippocampal neurons and then disrupted the microtubule cytoskeleton and caused neuritic degeneration, all in the absence of amyloid fibrils. Application of pure, synthetic dimers confirmed the effects of the natural AD dimers, although the former were far less potent. Knocking down endogenous tau fully prevented the neuritic changes, whereas overexpressing human tau accelerated them. Coadministering Aβ N-terminal antibodies neutralized the cytoskeletal disruption. We conclude that natural dimers isolated from the AD brain are sufficient to potently induce AD-type tau phosphorylation and then neuritic dystrophy, but passive immunotherapy mitigates this.Keywords
This publication has 44 references indexed in Scilit:
- A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer diseaseNeurology, 2009
- Divergent Pathways Mediate Spine Alterations and Cell Death Induced by Amyloid-β, Wild-Type Tau, and R406W TauJournal of Neuroscience, 2009
- Age-Dependent Impairment of Cognitive and Synaptic Function in the htau Mouse Model of Tau PathologyJournal of Neuroscience, 2009
- Soluble Oligomers of Amyloid β Protein Facilitate Hippocampal Long-Term Depression by Disrupting Neuronal Glutamate UptakeNeuron, 2009
- Oligomeric amyloid β associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaquesProceedings of the National Academy of Sciences of the United States of America, 2009
- Cellular prion protein mediates impairment of synaptic plasticity by amyloid-β oligomersNature, 2009
- Alzheimer's disease-type neuronal tau hyperphosphorylation induced by Aβ oligomersNeurobiology of Aging, 2008
- Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trialThe Lancet, 2008
- Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memoryNature Medicine, 2008
- Neurodegenerative TauopathiesAnnual Review of Neuroscience, 2001